Mr Papadopoulos will complement Regulus Therapeutics’s board of directors, which is comprised of industry leaders in drug discovery and development. Mr Papadopoulos retired as vice chairman of Cowen and Company in 2006.
Mr Papadopoulos holds a PhD in biophysics and an MBA in finance, both from New York University.
Kleanthis Xanthopoulos, president and CEO of Regulus, said: “We look forward to Dr Papadopoulos’s invaluable contributions as we continue to expand our therapeutic pipeline and bring lead microRNA therapeutic compounds closer to the clinic.”